← Patent-cliff monitor small molecule OPFOLDA MIGLUSTAT
Loss of exclusivity September 2038 latest FDA-listed patent expiry
Drug detail Brand name OPFOLDA Active ingredient MIGLUSTAT Strength 65MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval September 2023 Marketing status RX
Listed patents Patent Expires Type 12246062 September 2038 use U-3726 10857212 August 2037 use U-3726 11278601 December 2036 product 12414985 December 2036 use U-3726 11753632 September 2035 use U-3726 10208299 September 2035 substance, product 10961522 September 2035 use U-3726 11278599 March 2033 use U-3726 12419937 March 2033 use U-3726 10512677 March 2033 use U-3726
Regulatory exclusivity Code Expires NP September 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.